… gefitinib treatment in never-smokers and in patients of Asian origin. Here, we review the clinical
experience with gefitinib … remains for clinical development of gefitinib in selected patients. …

… This review discusses the use of gefitinib in Asian patients with advanced NSCLC using
the extensive clinical data available and also summarizes data on the discovery of the EGFR …

… Conference on Lung Cancer, the First-SIGNAL study, oral gefitinib confirmed an improvement
in progression-free survival compared to first-line chemotherapy in patients with EGFR …

… in persons with lung cancer. Many of the principles of management relevant to gefitinib are
distinct … practical guidelines on the use of gefitinib in patients with non–small-cell lung cancer. …

… a fraction of patients with NSCLC progressing after chemotherapy experience both a
decrease in lung cancer symptoms and radiographic tumor shrinkages with gefitinib.ObjectiveTo …

… Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, has a
… -small cell lung cancer (NSCLC). Several predictive factors of gefitinib sensitivity have been …

… Fifteen of the 79 patients who received gefitinib treatment in our institution had clinically
detectable BM at the time of gefitinib induction. Patient characteristics are shown in Table 1. …

… if it is possible to identify which patients may respond to gefitinib therapy, we … in patients
with advanced NSCLC before starting gefitinib therapy and evaluated their response to gefitinib …

… Optimum management strategies for patients with advanced non-small-cell lung cancer (…
of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with …

… 21% of gefitinib patients who had a dose reduction versus 47.9% of vinorelbine arm. No
toxicity-related death occurred in patients treated with gefitinib. In the INSTEP study Citation[21], …